Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neoadjuvant chemotherapy for bladder cancer: current status.

Robert Dreicer1

  • 1Department of Hematology/Oncology, Desk R35, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA. dreicer@cc.ccf.org

Expert Opinion on Pharmacotherapy
|June 5, 2003
PubMed
Summary

Neoadjuvant chemotherapy offers a survival benefit for select muscle-invasive bladder cancer patients. This review explores these pre-operative therapies and bladder-sparing approaches for improved outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relationship Among DNA Damage Response Gene Alterations, Molecular Subtypes, and Survival Outcomes in Patients With Metastatic Bladder Cancer Treated on CALGB 90601.

JCO precision oncology·2025
Same author

Incidental Brain Metastases From Prostate Cancer Diagnosed With PSMA PET/CT and MRI: A Case Series and Literature Review.

The Prostate·2025
Same author

COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Impact of Renin-Angiotensin System Inhibitors on Response to PD1/L1 Inhibitors in Patients With Metastatic Renal Cell Carcinoma.

Clinical genitourinary cancer·2024
Same author

When You Get to the Fork in the Road, Take It: The Challenges in Managing Patients With Advanced Prostate Cancer.

JCO oncology practice·2024
Same author

Impact of DPP4 Inhibition on Survival in Patients With Metastatic Renal Cell Carcinoma and Type 2 Diabetes Mellitus.

Clinical genitourinary cancer·2024

Area of Science:

  • Oncology
  • Urology
  • Cancer Research

Background:

  • Muscle-invasive bladder cancer (MIBC) is an aggressive malignancy with a high risk of early metastasis.
  • Radical cystectomy and radiotherapy are standard treatments but often followed by systemic failure.
  • Investigational strategies aim to improve survival rates in MIBC patients.

Purpose of the Study:

  • To review the role of neoadjuvant therapies in managing muscle-invasive bladder cancer.
  • To evaluate the impact of pre-operative chemotherapy on patient survival.
  • To discuss bladder-sparing treatment combinations for MIBC.

Main Methods:

  • Review of recently completed Phase III neoadjuvant chemotherapy trials.
  • Analysis of studies evaluating combined modality treatments for MIBC.

Related Experiment Videos

  • Focus on systemic chemotherapy administered prior to local treatment.

    • Main Results:

    • Phase III trials show a modest but significant survival advantage with neoadjuvant chemotherapy in a subset of MIBC patients.
    • Neoadjuvant chemotherapy is a viable strategy to improve outcomes for specific MIBC cases.
    • Combined approaches may offer bladder preservation options.

    Conclusions:

    • Neoadjuvant chemotherapy demonstrates potential to enhance survival for select muscle-invasive bladder cancer patients.
    • Further research into neoadjuvant strategies is crucial for optimizing MIBC management.
    • Bladder preservation techniques combined with systemic therapy warrant continued investigation.